Show simple item record

dc.contributor.authorAzhar, Shehnoor
dc.contributor.authorSaeed Khan, Khalid 
dc.date.accessioned2022-07-05T10:31:44Z
dc.date.available2022-07-05T10:31:44Z
dc.date.issued2022-05-18
dc.identifier.citationAzhar S... [et al.]. Protocol of Pakistan randomized and observational trial to evaluate coronavirus treatment among newly diagnosed patients with COVID-19: Azithromycin, Oseltamivir, and Hydroxychloquine. Pak J Med Sci. 2022;38(5):1401-1408. doi: [https://doi.org/10.12669/pjms.38.5.5512]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/75830
dc.description.abstractBackground & Objective: This study aimed to assess the clinical effectiveness of Hydroxychloroquine Sulfate (200 mg orally 8 hourlies thrice a day for 5 days), oseltamivir (75 mg orally twice a day for 5 days), and Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and in combination (in seven groups). Methods & Analysis: An adaptive design is deployed, set within a comprehensive cohort study, to permit flexibility in fast-changing clinical and public health scenario. Primary outcomes include turning the test negative for coronavirus nucliec acid and in bringing about clinical improvement on day 7 of follow-up on a seven-point ordinal scale. The randomized study will recruit participants of either gender above 18 years of age who will test positive for SARS-CoV-2 on Quantitative Reverse Transcription Polymerase Chain Reaction (PCR). Pregnant or lactating females, and those with severe respiratory distress, or with serious comorbidities will be excluded. Randomization will be done maintaining concealment of allocation sequence using a computer-generated random number list. The sample size will be subjected to periodic reviews by National Data Safety and Monitoring Board. Ethics and Dissemination: The trial is approved by the National Bioethics Committee (No.4-87/NBC- 471-COVID-19-05/20/) and institutional Ethical Review Committee. This clinical trial conducted under Good Clinical Practice is expected to inform patients clinical guidelines for the use of these drugs in newly diagnosed with SARS-CoV-2.es_ES
dc.description.sponsorshipSpanish Governmentes_ES
dc.language.isoenges_ES
dc.publisherProfessional Medical Publicationses_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectSARS-CoV-2es_ES
dc.subjectHydroxychloroquinees_ES
dc.subjectAzithromycines_ES
dc.subjectOseltamivires_ES
dc.subjectMulti-centeres_ES
dc.subjectAdaptivees_ES
dc.subjectRandomizationes_ES
dc.subjectHealth es_ES
dc.subjectOff-labeles_ES
dc.titleProtocol of Pakistan randomized and observational trial to evaluate coronavirus treatment among newly diagnosed patients with COVID-19: Azithromycin, Oseltamivir, and Hydroxychloquinees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.12669/pjms.38.5.5512
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional